Careers | Contact Us

Press Releases
January 23, 2011
BioLineRx has been advised by Royalty Pharma, the new parent company of Cypress Bioscience Inc., that it is committed to enhance the value of Cypress’ pipeline assets, including BioLineRx’s BL-1020 (CYP-1020) .
January 4, 2011

Office of the Chief Scientist at the Israeli Ministry of Industry, Trade and Labor (OCS) has renewed BioLineRx's franchise for the biotechnology incubator, BioLine Innovations Jerusalem (BIJ), for an additional two years.
December 28, 2010

Dr. Kinneret Savitsky: "We are happy with the positive results of the clinical trial, which fulfill our expectations regarding BL-5010’s efficacy and safety."

November 29, 2010

BioLineRx will participate in an investor conference highlighting the life-sciences industry on December 6, 2010, co-sponsored by NASDAQ and the Tel-Aviv Stock Exchange (TASE).

November 24, 2010
Dr. Kinneret Savitsky, BioLineRx CEO: "These results reinforce our business model and the significant progress made by the Company, as well as our bottom-line profitability, which is unusual for a company in the biotech sector. BioLineRx is focused on generating value for our shareholders and we will continue working intensively to promote our projects. "
October 27, 2010
Important scientific and professional recognition for BioLineRx:
Distinguished poster award for research quality received at ISCTM for Phase IIb trial of BL-1020 (CYP-1020), novel molecule for schizophrenia
August 30, 2010
Data will be presented on 2nd September at World Congress on Pain, the world's largest pain related gathering
August 24, 2010
Company milestone - EDP-01 is the first graduate of EDP program to enter the Company's main product pipeline

August 11, 2010
At closing, $30 million upfront payment was released from escrow to BioLineRx
281-290  Out of  309 Previous
 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
 16   17   18   19   20   21   22   23   24   25   26   27   28   29 
 30   31